Emerging and Experimental Agents for Anal Cancer: What is New?

Retrieved on: 2021-04-09 01:07:30

Tags for this article:

Click the tags to see associated articles and topics

Emerging and Experimental Agents for Anal Cancer: What is New?. View article details on hiswai:

Excerpt

Immune checkpoint inhibitors (ICIs), mainly anti-PD-1 monoclonal antibodies, such as retifanlimab, nivolumab, and atezolizumab have been studied in ...

Article found on: www.dovepress.com

View Original Article